GoodRx Holdings, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| (in thousands) | 2026 | 2025 |
| Cash flows from operating activities | ||
| Net income | $1,169 | $11,052 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 21,792 | 20,912 |
| Amortization of debt issuance costs and discounts | 462 | 430 |
| Non-cash operating lease expense | 925 | 1,086 |
| Stock-based compensation expense | 16,509 | 19,174 |
| Deferred income taxes | 4,069 | — |
| Loss on operating lease asset | — | 4,409 |
| Other | 798 | 286 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 3,025 | (14,183) |
| Prescription reimbursement assets (1) | (655,199) | (14,391) |
| Prepaid expenses and other assets (1) | 2,177 | 904 |
| Accounts payable | (4,945) | 286 |
| Prescription reimbursement liabilities (1) | 620,839 | (8,520) |
| Accrued expenses and other current liabilities (1) | 1,744 | (10,559) |
| Operating lease liabilities | (1,478) | (1,628) |
| Other liabilities | (49) | 155 |
| Net cash provided by operating activities | 11,838 | 9,413 |
| Cash flows from investing activities | ||
| Purchase of property and equipment | (1,136) | (142) |
| Acquisition | — | (30,000) |
| Capitalized software | (20,508) | (21,734) |
| Net cash used in investing activities | (21,644) | (51,876) |
| Cash flows from financing activities | ||
| Payments on long-term debt | (1,250) | (1,250) |
| Repurchases of Class A common stock (2) | (12,567) | (99,897) |
| Proceeds from exercise of stock options | 95 | 2 |
| Employee taxes paid related to net share settlement of equity awards | (2,582) | (3,757) |
| Net cash used in financing activities | (16,304) | (104,902) |
| Net change in cash and cash equivalents | (26,110) | (147,365) |
| Cash and cash equivalents | ||
| Beginning of period | 261,820 | 448,346 |
| End of period | $235,710 | $300,981 |
| Supplemental disclosure of cash flow information | ||
| Non cash investing and financing activities: | ||
| Stock-based compensation included in capitalized software | $3,174 | $4,138 |
| Capitalized software included in accounts payable and accrued expenses and other current liabilities | 3,806 | 5,311 |
(1)Prior to December 31, 2025, prescription reimbursement assets were presented as a component of prepaid
expenses and other current assets, and prescription reimbursement liabilities as a component ofaccrued expenses
and other current liabilities. Prior period amounts have been reclassified to conform to the current period
presentation. These reclassifications had no impact on previously reported cash flows provided by operating
activities.
(2)Repurchases of Class A common stock for thethree months ended March 31, 2025 include 20.0 million shares
repurchased from related parties (after giving effect to the automatic conversion of Class B common stock to Class
A common stock upon such repurchase) for an aggregate consideration of$84.9 million. See "Note 9.
Stockholders' Equity" for additional information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.